Dennis Serge Metselaar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dennis Serge Metselaar has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Esther Hulleman
Department of Neuro-oncology, Princess Máxima Center for Paediatric Oncology, Heidelberglaan 25, 3584CS Utrecht, the Netherlands
10 shared publicationsGertjan J.L. Kaspers
Departments of Pediatric Oncology/Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers
10 shared publicationsMarianna Bugiani
Department of Pathology, Amsterdam University Medical Centers
10 shared publicationsMarjolein Breur
Department of Pathology, Amsterdam University Medical Centers
10 shared publications- Mark Cornelis de Gooijer
Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
10 shared publications - Piotr Waranecki
VU University Medical Center, Amsterdam, The Netherlands
10 shared publications
Latest Publications
- Open Access
- 27 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (7) , 1612-1624
Attract to kill: Exploring the potential of motility trapping as a novel treatment strategy for high-grade gliomas
High-grade gliomas (HGG) are notoriously hard to treat due to surgical limitations and resistance to systemic therapies, resulting in a dire prognosis. Tumor cell motility is a major contributor to treatment failure but simultaneously offers a therapeutic opportunity, utilizing a novel approach called “motility trapping”. Motility trapping leverages chemotactic signals to redirect tumor cells to a location where local therapies can target them more effectively. This concept can be applied inward, drawing disseminated tumor cells back to the primary tumor, or outward, guiding them toward a more therapy-accessible location. While preclinical research demonstrates that motility trapping can influence tumor migration, clinical translation remains unestablished. To advance clinical applicability, 4 essential components must be considered: effective migratory stimuli, susceptible tumor cells, suitable delivery systems, and the influence of the tumor microenvironment. For each element, we review current knowledge and propose future directions to develop this innovative approach. In conclusion, redirecting HGG migration through motility trapping offers a transformative strategy that warrants further preclinical and translational investigation. It holds promise to synergize with a plethora of therapeutic strategies that are currently ineffective in brain tumors and should be considered in the design of future therapies.
- 27 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (7) , 1612-1624
Open AccessAttract to kill: Exploring the potential of motility trapping as a novel treatment strategy for high-grade gliomas
High-grade gliomas (HGG) are notoriously hard to treat due to surgical limitations and resistance to systemic therapies, resulting in a dire prognosis. Tumor cell motility is a major contributor to treatment failure but simultaneously offers a therapeutic opportunity, utilizing a novel approach called “motility trapping”. Motility trapping leverages chemotactic signals to redirect tumor cells to a location where local therapies can target them more effectively. This concept can be applied inward, drawing disseminated tumor cells back to the primary tumor, or outward, guiding them toward a more therapy-accessible location. While preclinical research demonstrates that motility trapping can influence tumor migration, clinical translation remains unestablished. To advance clinical applicability, 4 essential components must be considered: effective migratory stimuli, susceptible tumor cells, suitable delivery systems, and the influence of the tumor microenvironment. For each element, we review current knowledge and propose future directions to develop this innovative approach. In conclusion, redirecting HGG migration through motility trapping offers a transformative strategy that warrants further preclinical and translational investigation. It holds promise to synergize with a plethora of therapeutic strategies that are currently ineffective in brain tumors and should be considered in the design of future therapies.
- Open Access
- 25 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (2)
CAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models
Aggressive pediatric brain tumor models of ependymoma are highly sensitive to GD2-directed (CAR T) cell therapy
- 25 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (2)
Open AccessCAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models
Aggressive pediatric brain tumor models of ependymoma are highly sensitive to GD2-directed (CAR T) cell therapy
- Open Access
The Complexity of Malignant Glioma Treatment
Malignant glioma is a highly aggressive, therapeutically non-responsive, and deadly disease with a unique tumor microenvironment (TME). Of the 14 currently recognized and described cancer hallmarks, five are especially implicated in malignant glioma and targetable with repurposed drugs: cancer stem-like cells, in general, and glioma stem-like cells in particular (GSCs), vascularization and hypoxia, metabolic reprogramming, tumor-promoting inflammation and sustained proliferative signaling. Each hallmark drives malignant glioma development, both individually and through interactions with other hallmarks, in which the TME plays a critical role. To combat the aggressive malignant glioma spatio-temporal heterogeneity driven by TME interactions, and to overcome its therapeutic challenges, a combined treatment strategy including anticancer therapies, repurposed drugs and multimodal immunotherapy should be the aim for future treatment approaches.
Open AccessThe Complexity of Malignant Glioma Treatment
Malignant glioma is a highly aggressive, therapeutically non-responsive, and deadly disease with a unique tumor microenvironment (TME). Of the 14 currently recognized and described cancer hallmarks, five are especially implicated in malignant glioma and targetable with repurposed drugs: cancer stem-like cells, in general, and glioma stem-like cells in particular (GSCs), vascularization and hypoxia, metabolic reprogramming, tumor-promoting inflammation and sustained proliferative signaling. Each hallmark drives malignant glioma development, both individually and through interactions with other hallmarks, in which the TME plays a critical role. To combat the aggressive malignant glioma spatio-temporal heterogeneity driven by TME interactions, and to overcome its therapeutic challenges, a combined treatment strategy including anticancer therapies, repurposed drugs and multimodal immunotherapy should be the aim for future treatment approaches.
- Open Access
CAR-based therapeutic targets in pediatric high-grade glioma
High-grade glioma (HGG) patients have a dismal prognosis, due to a lack of effective treatments. In order to change the fate of HGG patients and decrease the current treatment-related side effects, therapy focus has shifted in the past years to immunotherapy, such as chimeric antigen receptor (CAR)-based treatments. Recent developments in CAR-based therapy show promising results in adult glioma patients, and the first clinical trials for pediatric patients with HGG are in progress. However, there are significant differences between pediatric HGG (pHGG) and their adult counterparts, including the composition of the tumor immune microenvironment (TIME), which strongly influences CAR treatment responsiveness. Therefore, we here provide a systematic overview of CAR-based therapeutic targets in pHGG entities, focusing on clinical trials and preclinical research, and comparing them to adult glioma. We conclude that target expression, TIME and CAR treatment-related toxicities vary across pHGG entities and differ from adult HGG, which suggests the need for more tailored immunotherapeutic CAR approaches in pHGG. Overall, we provide a target roadmap for future development of CAR-based therapeutic strategies for pediatric HGG patients, who are in desperate need for novel therapies. Graphical The number of potential CAR-based therapeutic targets for glioblastoma and pHGG. CAR: Chimeric antigen receptor; pHGG: pediatric high-grade glioma; DHG: H3 G34-mutant diffuse hemispheric glioma; DMG: H3 K27-altered diffuse midline glioma; PFA: posterior fossa ependymoma type A. Image was created in Biorender.com .
Open AccessCAR-based therapeutic targets in pediatric high-grade glioma
High-grade glioma (HGG) patients have a dismal prognosis, due to a lack of effective treatments. In order to change the fate of HGG patients and decrease the current treatment-related side effects, therapy focus has shifted in the past years to immunotherapy, such as chimeric antigen receptor (CAR)-based treatments. Recent developments in CAR-based therapy show promising results in adult glioma patients, and the first clinical trials for pediatric patients with HGG are in progress. However, there are significant differences between pediatric HGG (pHGG) and their adult counterparts, including the composition of the tumor immune microenvironment (TIME), which strongly influences CAR treatment responsiveness. Therefore, we here provide a systematic overview of CAR-based therapeutic targets in pHGG entities, focusing on clinical trials and preclinical research, and comparing them to adult glioma. We conclude that target expression, TIME and CAR treatment-related toxicities vary across pHGG entities and differ from adult HGG, which suggests the need for more tailored immunotherapeutic CAR approaches in pHGG. Overall, we provide a target roadmap for future development of CAR-based therapeutic strategies for pediatric HGG patients, who are in desperate need for novel therapies. Graphical The number of potential CAR-based therapeutic targets for glioblastoma and pHGG. CAR: Chimeric antigen receptor; pHGG: pediatric high-grade glioma; DHG: H3 G34-mutant diffuse hemispheric glioma; DMG: H3 K27-altered diffuse midline glioma; PFA: posterior fossa ependymoma type A. Image was created in Biorender.com .
- Open Access
- 3 November 2023
- Published by Elsevier in Cell Reports Medicine
- Vol. 4 (11) , 101246
Microglia in pediatric brain tumors: The missing link to successful immunotherapy
- 3 November 2023
- Published by Elsevier in Cell Reports Medicine
- Vol. 4 (11) , 101246
Open AccessMicroglia in pediatric brain tumors: The missing link to successful immunotherapy
- Open Access
Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in Atypical Teratoid/Rhabdoid Tumors
Background Atypical Teratoid/Rhabdoid Tumors (ATRT) are highly malignant embryonal tumors of the central nervous system with a dismal prognosis. Despite recent advances in understanding the molecular characteristics and subclasses of these tumors, effective therapeutic options remain scarce. Methods In this study, we developed and validated a novel patient-derived ATRT culture and xenograft model, which we used alongside a panel of other primary ATRT models for large-scale drug discovery assays. The identified hits were mechanistically and therapeutically investigated using an array of molecular assays and two orthotopic xenograft murine models. Results We found that ATRT are selectively sensitive to the nucleoside analogue gemcitabine, with additional efficacy in Sonic Hedgehog (SHH)-subtype ATRT. Gene expression profiles and protein analyses indicated that gemcitabine treatment causes degradation of Sirtuin 1 (SIRT1), resulting in cell death through activation of NF-kB and p53. Furthermore, we discovered that gemcitabine-induced loss of SIRT1 results in a nucleus-to-cytoplasm translocation of the SHH signaling activator GLI2, explaining the additional gemcitabine sensitivity in SHH-subtype ATRT. Treatment of SHH-subgroup ATRT xenograft-bearing mice with gemcitabine resulted in a >30% increase in median survival (pConclusions These findings demonstrate that ATRT are highly sensitive to gemcitabine treatment, and we propose that gemcitabine may form part of a future multimodal treatment strategy for ATRT. Key points - ATRT are specifically sensitive to gemcitabine treatment - SIRT1 may serve as a novel therapeutic target in ATRT - Gemcitabine should be considered for clinical use in ATRT patients Importance of the study Atypical Teratoid/Rhabdoid Tumors (ATRT) are highly malignant pediatric brain tumors with a 5-year survival of merely 30%, for which effective treatment options are limited. In this study, we propose a potential novel treatment strategy for ATRT patients. We show that ATRT are highly sensitive to the chemotherapeutic gemcitabine, that takes advantage of ATRT-specific SIRT1 overexpression and disrupts p53 suppression and hedgehog signaling. Importantly, we show that gemcitabine significantly prolongs survival of ATRT patient-derived xenograft models, prolonging survival by over 30%. This effect was achieved using gemcitabine concentrations that are achievable in human brain and well-tolerated in pediatric patients. As such, gemcitabine could be readily incorporated into clinical treatment protocols and expand the still very limited therapeutic options for ATRT-patients.
Open AccessGemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in Atypical Teratoid/Rhabdoid Tumors
Background Atypical Teratoid/Rhabdoid Tumors (ATRT) are highly malignant embryonal tumors of the central nervous system with a dismal prognosis. Despite recent advances in understanding the molecular characteristics and subclasses of these tumors, effective therapeutic options remain scarce. Methods In this study, we developed and validated a novel patient-derived ATRT culture and xenograft model, which we used alongside a panel of other primary ATRT models for large-scale drug discovery assays. The identified hits were mechanistically and therapeutically investigated using an array of molecular assays and two orthotopic xenograft murine models. Results We found that ATRT are selectively sensitive to the nucleoside analogue gemcitabine, with additional efficacy in Sonic Hedgehog (SHH)-subtype ATRT. Gene expression profiles and protein analyses indicated that gemcitabine treatment causes degradation of Sirtuin 1 (SIRT1), resulting in cell death through activation of NF-kB and p53. Furthermore, we discovered that gemcitabine-induced loss of SIRT1 results in a nucleus-to-cytoplasm translocation of the SHH signaling activator GLI2, explaining the additional gemcitabine sensitivity in SHH-subtype ATRT. Treatment of SHH-subgroup ATRT xenograft-bearing mice with gemcitabine resulted in a >30% increase in median survival (pConclusions These findings demonstrate that ATRT are highly sensitive to gemcitabine treatment, and we propose that gemcitabine may form part of a future multimodal treatment strategy for ATRT. Key points - ATRT are specifically sensitive to gemcitabine treatment - SIRT1 may serve as a novel therapeutic target in ATRT - Gemcitabine should be considered for clinical use in ATRT patients Importance of the study Atypical Teratoid/Rhabdoid Tumors (ATRT) are highly malignant pediatric brain tumors with a 5-year survival of merely 30%, for which effective treatment options are limited. In this study, we propose a potential novel treatment strategy for ATRT patients. We show that ATRT are highly sensitive to the chemotherapeutic gemcitabine, that takes advantage of ATRT-specific SIRT1 overexpression and disrupts p53 suppression and hedgehog signaling. Importantly, we show that gemcitabine significantly prolongs survival of ATRT patient-derived xenograft models, prolonging survival by over 30%. This effect was achieved using gemcitabine concentrations that are achievable in human brain and well-tolerated in pediatric patients. As such, gemcitabine could be readily incorporated into clinical treatment protocols and expand the still very limited therapeutic options for ATRT-patients.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary table S1 from Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma
Sequences of shRNA constructs used in the present study.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table S1 from Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma
Sequences of shRNA constructs used in the present study.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary figures from Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma
File containing all supplementary figures
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figures from Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma
File containing all supplementary figures
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data Legends from Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma
Legends pertaining to supplementary figures and tables
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Legends from Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma
Legends pertaining to supplementary figures and tables
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma
Purpose:Diffuse intrinsic pontine glioma (DIPG) is an incurable type of pediatric brain cancer, which in the majority of cases is driven by mutations in genes encoding histone 3 (H3K27M). We here determined the preclinical therapeutic potential of combined AXL and HDAC inhibition in these tumors to reverse their mesenchymal, therapy-resistant, phenotype.Experimental Design:We used public databases and patient-derived DIPG cells to identify putative drivers of the mesenchymal transition in these tumors. Patient-derived neurospheres, xenografts, and allografts were used to determine the therapeutic potential of combined AXL/HDAC inhibition for the treatment of DIPG.Results:We identified AXL as a therapeutic target and regulator of the mesenchymal transition in DIPG. Combined AXL and HDAC inhibition had a synergistic and selective antitumor effect on H3K27M DIPG cells. Treatment of DIPG cells with the AXL inhibitor BGB324 and the HDAC inhibitor panobinostat resulted in a decreased expression of mesenchymal and stem cell genes. Moreover, this combination treatment decreased expression of DNA damage repair genes in DIPG cells, strongly sensitizing them to radiation. Pharmacokinetic studies showed that BGB324, like panobinostat, crosses the blood–brain barrier. Consequently, treatment of patient-derived DIPG xenograft and murine DIPG allograft-bearing mice with BGB324 and panobinostat resulted in a synergistic antitumor effect and prolonged survival.Conclusions:Combined inhibition of AXL and HDACs in DIPG cells results in a synergistic antitumor effect by reversing their mesenchymal, stem cell-like, therapy-resistant phenotype. As such, this treatment combination may serve as part of a future multimodal therapeutic strategy for DIPG.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma
Purpose:Diffuse intrinsic pontine glioma (DIPG) is an incurable type of pediatric brain cancer, which in the majority of cases is driven by mutations in genes encoding histone 3 (H3K27M). We here determined the preclinical therapeutic potential of combined AXL and HDAC inhibition in these tumors to reverse their mesenchymal, therapy-resistant, phenotype.Experimental Design:We used public databases and patient-derived DIPG cells to identify putative drivers of the mesenchymal transition in these tumors. Patient-derived neurospheres, xenografts, and allografts were used to determine the therapeutic potential of combined AXL/HDAC inhibition for the treatment of DIPG.Results:We identified AXL as a therapeutic target and regulator of the mesenchymal transition in DIPG. Combined AXL and HDAC inhibition had a synergistic and selective antitumor effect on H3K27M DIPG cells. Treatment of DIPG cells with the AXL inhibitor BGB324 and the HDAC inhibitor panobinostat resulted in a decreased expression of mesenchymal and stem cell genes. Moreover, this combination treatment decreased expression of DNA damage repair genes in DIPG cells, strongly sensitizing them to radiation. Pharmacokinetic studies showed that BGB324, like panobinostat, crosses the blood–brain barrier. Consequently, treatment of patient-derived DIPG xenograft and murine DIPG allograft-bearing mice with BGB324 and panobinostat resulted in a synergistic antitumor effect and prolonged survival.Conclusions:Combined inhibition of AXL and HDACs in DIPG cells results in a synergistic antitumor effect by reversing their mesenchymal, stem cell-like, therapy-resistant phenotype. As such, this treatment combination may serve as part of a future multimodal therapeutic strategy for DIPG.